TY - JOUR
T1 - Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction
AU - Hishikawa, Nozomi
AU - Fukui, Yusuke
AU - Sato, Kota
AU - Ohta, Yasuyuki
AU - Yamashita, Toru
AU - Abe, Koji
N1 - Funding Information:
This work was partly supported by a Grant-in-Aid for Scientific Research (B) 2529320216, (C) 24591263 and Challenging Research 24659651, and by Grants-in-Aid from the Research Committees (H Mizusawa, K Nakashima, M Nishizawa, H Sasaki and M Aoki) from the Ministry of Health, Labor and Welfare of Japan.
PY - 2017/10
Y1 - 2017/10
N2 - Aim: The coexistence of Alzheimer's disease (AD) and cerebrovascular disease pathology increases age-dependently. We comprehensively analyzed the clinical effects of galantamine or cilostazol monotherapy to the add-on combination therapy on three major factors of dementia, such as cognitive, affective and activities of daily living functions in AD patients with asymptomatic lacunar infarction. Methods: We divided 101 AD patients with asymptomatic lacunar infarction into two subgroups: group A (n = 61, first treated with galantamine and then cilostazol added) and group B (n = 40, first treated with cilostazol and galantamine added). We compared the clinical effects before and after combination therapy of galantamine and cilostazol (i.e. 3 months [M] before (–3 M), baseline (0 M), 3 and 6 M after the add-on combination). Results: Galantamine monotherapy increased cognitive Hasegawa dementia score-revised scores, which were further improved with add-on cilostazol. Cilostazol monotherapy also increased the cognitive tests, which were further improved with add-on galantamine. Add-on cilostazol significantly improved Geriatric Depression Scale and Abe's behavioral and psychological symptoms of dementia scores after galantamine monotherapy. Cilostazol monotherapy also significantly improved Geriatric Depression Scale scores, with further improvements in Geriatric Depression Scale, apathy scores and Abe's behavioral and psychological symptoms of dementia scores by add-on galantamine. Activities of daily living scores continuously improved with galantamine monotherapy and add-on cilostazol. Conclusions: The present study provides a clinical possibility that galantamine or cilostazol monotherapy and the combination therapy maintained or even improved cognitive, affective, and activities of daily living functions in AD with asymptomatic lacunar infarction. Geriatr Gerontol Int 2017; 17: 1384–1391.
AB - Aim: The coexistence of Alzheimer's disease (AD) and cerebrovascular disease pathology increases age-dependently. We comprehensively analyzed the clinical effects of galantamine or cilostazol monotherapy to the add-on combination therapy on three major factors of dementia, such as cognitive, affective and activities of daily living functions in AD patients with asymptomatic lacunar infarction. Methods: We divided 101 AD patients with asymptomatic lacunar infarction into two subgroups: group A (n = 61, first treated with galantamine and then cilostazol added) and group B (n = 40, first treated with cilostazol and galantamine added). We compared the clinical effects before and after combination therapy of galantamine and cilostazol (i.e. 3 months [M] before (–3 M), baseline (0 M), 3 and 6 M after the add-on combination). Results: Galantamine monotherapy increased cognitive Hasegawa dementia score-revised scores, which were further improved with add-on cilostazol. Cilostazol monotherapy also increased the cognitive tests, which were further improved with add-on galantamine. Add-on cilostazol significantly improved Geriatric Depression Scale and Abe's behavioral and psychological symptoms of dementia scores after galantamine monotherapy. Cilostazol monotherapy also significantly improved Geriatric Depression Scale scores, with further improvements in Geriatric Depression Scale, apathy scores and Abe's behavioral and psychological symptoms of dementia scores by add-on galantamine. Activities of daily living scores continuously improved with galantamine monotherapy and add-on cilostazol. Conclusions: The present study provides a clinical possibility that galantamine or cilostazol monotherapy and the combination therapy maintained or even improved cognitive, affective, and activities of daily living functions in AD with asymptomatic lacunar infarction. Geriatr Gerontol Int 2017; 17: 1384–1391.
KW - Alzheimer's disease
KW - asymptomatic lacunar infarction
KW - cilostazol
KW - cognitive/affective functions
KW - galantamine
UR - http://www.scopus.com/inward/record.url?scp=84984684802&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984684802&partnerID=8YFLogxK
U2 - 10.1111/ggi.12870
DO - 10.1111/ggi.12870
M3 - Article
C2 - 27578455
AN - SCOPUS:84984684802
VL - 17
SP - 1384
EP - 1391
JO - Geriatrics and Gerontology International
JF - Geriatrics and Gerontology International
SN - 1447-0594
IS - 10
ER -